Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganciclovir ophthalmic - Laboratoires Thea

Next Previous
Drug Profile

Ganciclovir ophthalmic - Laboratoires Thea

Alternative Names: Ganciclovir ophthalmic gel 0.15%; ST-605; Virgan; Zirgan

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratoires Thea
  • Developer Laboratoires Thea; Ms Science; Rohto Pharmaceutical; Sirion Therapeutics
  • Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ocular herpes simplex
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular herpes simplex
  • Phase III Cytomegalovirus infections
  • Phase II Dendritic keratitis

Most Recent Events

  • 09 Apr 2025 Adverse events and efficacy data from a phase III trial in Cytomegalovirus infections released by Rohto Pharmaceuticals
  • 31 Dec 2022 Rohto Pharmaceuticals completes a phase III trial in Cytomegalovirus infections in Japan (Ophthalmic) (jRCT2051210064)
  • 01 Mar 2021 Phase-III clinical trials in Cytomegalovirus infections in Japan (Ophthalmic) (jRCT2051210064)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top